The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Autem Therapeutics; BeOne therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeOne therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Jason Henry
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbisko (Inst); ABL Bio (Inst); accutar biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Artios (Inst); AstraZeneca/Merck (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); Bioinvent (Inst); Biosplice (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); cyteir (Inst); DaiichI Sankyo (Inst); Daiichi Sankyo/Lilly (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); IgM Biosciences (Inst); Immunitas (Inst); Immunogen (Inst); Immunogen (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Metabomed (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Oncorus (Inst); Poseida therapeutics (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Sarah Cannon Research Institute (Inst); Seagan (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Stingthera (Inst); StingThera (Inst); Synthorx (Inst); Synthorx (Inst); Takeda (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); Teneothree (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - HCA/Sarah Cannon (Inst)
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Naomi Fei
No Relationships to Disclose
 
Nicholas DeVito
Employment - Duke University
Stock and Other Ownership Interests - Corvus Pharmaceuticals (I)
Honoraria - AlphaSights Consulting; Gerson Lehrman Group
Consulting or Advisory Role - Agenus; Guardant Health; Incyte; Xilio Therapeutics
Research Funding - Astellas Pharma (Inst); GlaxoSmithKline (Inst); Merck; Phanes Therapeutics (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - Agenus
 
Nataliya Uboha
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; BeiGene; Eisai; Elevation Oncology; Gilead Sciences; Ipsen; Jazz Pharmaceuticals; Leap Therapeutics; Lilly; Merck; Natera; Strata Oncology
Research Funding - Arcus Biosciences (Inst); EMD Serono (Inst); ipsen (Inst)
Travel, Accommodations, Expenses - BeiGene
 
Dani Castillo
Consulting or Advisory Role - Amgen
 
Grace McGregor
Employment - Phanes Therapeutics, Inc
Stock and Other Ownership Interests - Phanes Therapeutics, Inc
 
Hui Zou
Employment - Phanes Therapeutics, Inc
Leadership - Phanes Therapeutics, Inc
Stock and Other Ownership Interests - Phanes Therapeutics, Inc
Patents, Royalties, Other Intellectual Property - Phanes Therapeutics, Inc
 
Ming Wang
Employment - Phanes Therapeutics, Inc
Leadership - Phanes Therapeutics, Inc
Stock and Other Ownership Interests - Phanes Therapeutics, Inc
Patents, Royalties, Other Intellectual Property - Phanes Therapeutics, Inc
 
Satya Das
Employment - Phanes Therapeutics, Inc
Stock and Other Ownership Interests - Phanes Therapeutics, Inc
Consulting or Advisory Role - Tegus; Third Bridge
 
Rita Laeufle
Employment - Phanes Therapeutics, Inc
Leadership - Phanes Therapeutics, Inc
Stock and Other Ownership Interests - Phanes Therapeutics, Inc
Patents, Royalties, Other Intellectual Property - Merck Serono
 
Harshabad Singh
Honoraria - UpToDate
Consulting or Advisory Role - Dewpoint Therapeutics; Merck; Zola Therapeutics
Speakers' Bureau - Peerdirect
Research Funding - AstraZeneca/Daiichi Sankyo
Travel, Accommodations, Expenses - Dava Oncology